Phase 3 Lung Cancer Trial, Recruiting NCT05236946 Sponsor: Tata Memorial Hospital Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT05236946
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People whose general health and ability to carry out daily activities falls within a certain range, rated on a standard medical scale (confirm with trial site)
  • People who have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC), confirmed by laboratory testing of tissue
  • People whose lung cancer has a specific genetic change in either the EGFR or ALK gene
  • People who have cancer that has spread to the brain tissue, confirmed by imaging scans
  • People whose brain metastases are not currently causing symptoms, whether the brain spread was found at the same time as the original cancer or developed later
  • People who are willing to sign a consent form and agree to attend follow-up appointments as required by the trial

Who may not be able to join:

  • People whose cancer has spread only to the fluid surrounding the brain and spinal cord, without any spread into the brain tissue itself
  • People who have cancer that has spread to the brain stem specifically
  • People who have previously had radiation therapy to the brain
  • People who are not considered suitable for a type of targeted cancer medication called a TKI, as determined by their cancer specialist
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 9122 2417 7000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tata Memorial Hospital
Registry
ClinicalTrials.gov
Start date
10 November 2020
Est. completion
1 December 2025

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Intracranial progression free survival at 24 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov